|
Gene: SERPINB5 |
Gene summary for SERPINB5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SERPINB5 | Gene ID | 5268 |
Gene name | serpin family B member 5 | |
Gene Alias | PI5 | |
Cytomap | 18q21.33 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R2B6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5268 | SERPINB5 | CA_HPV_1 | Human | Cervix | CC | 2.14e-04 | -2.16e-01 | 0.0264 |
5268 | SERPINB5 | CA_HPV_2 | Human | Cervix | CC | 7.92e-06 | 3.27e-01 | 0.0391 |
5268 | SERPINB5 | CA_HPV_3 | Human | Cervix | CC | 4.96e-03 | 9.06e-02 | 0.0414 |
5268 | SERPINB5 | Tumor | Human | Cervix | CC | 1.24e-77 | 1.22e+00 | 0.1241 |
5268 | SERPINB5 | sample3 | Human | Cervix | CC | 5.08e-92 | 1.20e+00 | 0.1387 |
5268 | SERPINB5 | L1 | Human | Cervix | CC | 9.35e-03 | 3.78e-01 | 0.0802 |
5268 | SERPINB5 | T3 | Human | Cervix | CC | 9.52e-85 | 1.22e+00 | 0.1389 |
5268 | SERPINB5 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.55e-04 | 1.47e-01 | 0.0155 |
5268 | SERPINB5 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.80e-07 | 3.54e-01 | -0.1808 |
5268 | SERPINB5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.39e-17 | 5.52e-01 | -0.0811 |
5268 | SERPINB5 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.54e-12 | 4.35e-01 | -0.1088 |
5268 | SERPINB5 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.78e-05 | 5.36e-01 | -0.2602 |
5268 | SERPINB5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.00e-12 | 4.56e-01 | -0.059 |
5268 | SERPINB5 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.45e-03 | 1.82e-01 | 0.0528 |
5268 | SERPINB5 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.09e-05 | 1.93e-01 | 0.0588 |
5268 | SERPINB5 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.96e-10 | 2.26e-01 | 0.294 |
5268 | SERPINB5 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.42e-04 | 5.35e-01 | 0.3487 |
5268 | SERPINB5 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.93e-12 | 3.68e-01 | 0.281 |
5268 | SERPINB5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.03e-09 | 2.20e-01 | 0.3859 |
5268 | SERPINB5 | LZE4T | Human | Esophagus | ESCC | 6.39e-04 | 6.17e-01 | 0.0811 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002261215 | Oral cavity | LP | gland morphogenesis | 41/4623 | 118/18723 | 9.09e-03 | 4.85e-02 | 41 |
GO:005254725 | Oral cavity | EOLP | regulation of peptidase activity | 105/2218 | 461/18723 | 1.86e-11 | 2.79e-09 | 105 |
GO:005254825 | Oral cavity | EOLP | regulation of endopeptidase activity | 98/2218 | 432/18723 | 1.12e-10 | 1.29e-08 | 98 |
GO:004586125 | Oral cavity | EOLP | negative regulation of proteolysis | 72/2218 | 351/18723 | 1.96e-06 | 4.49e-05 | 72 |
GO:006145824 | Oral cavity | EOLP | reproductive system development | 81/2218 | 427/18723 | 1.09e-05 | 1.93e-04 | 81 |
GO:004860823 | Oral cavity | EOLP | reproductive structure development | 80/2218 | 424/18723 | 1.51e-05 | 2.50e-04 | 80 |
GO:001095124 | Oral cavity | EOLP | negative regulation of endopeptidase activity | 52/2218 | 252/18723 | 4.21e-05 | 5.74e-04 | 52 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:001046624 | Oral cavity | EOLP | negative regulation of peptidase activity | 52/2218 | 262/18723 | 1.21e-04 | 1.34e-03 | 52 |
GO:004873224 | Oral cavity | EOLP | gland development | 77/2218 | 436/18723 | 2.05e-04 | 2.06e-03 | 77 |
GO:005067317 | Oral cavity | EOLP | epithelial cell proliferation | 75/2218 | 437/18723 | 5.90e-04 | 4.97e-03 | 75 |
GO:003019811 | Oral cavity | EOLP | extracellular matrix organization | 52/2218 | 301/18723 | 3.29e-03 | 1.90e-02 | 52 |
GO:004306211 | Oral cavity | EOLP | extracellular structure organization | 52/2218 | 302/18723 | 3.52e-03 | 2.01e-02 | 52 |
GO:004522911 | Oral cavity | EOLP | external encapsulating structure organization | 52/2218 | 304/18723 | 4.04e-03 | 2.23e-02 | 52 |
GO:003085012 | Oral cavity | EOLP | prostate gland development | 12/2218 | 45/18723 | 5.03e-03 | 2.65e-02 | 12 |
GO:005067816 | Oral cavity | EOLP | regulation of epithelial cell proliferation | 61/2218 | 381/18723 | 8.75e-03 | 4.06e-02 | 61 |
GO:005254733 | Oral cavity | NEOLP | regulation of peptidase activity | 98/2005 | 461/18723 | 1.77e-11 | 2.56e-09 | 98 |
GO:006145831 | Oral cavity | NEOLP | reproductive system development | 91/2005 | 427/18723 | 8.18e-11 | 9.00e-09 | 91 |
GO:004860831 | Oral cavity | NEOLP | reproductive structure development | 90/2005 | 424/18723 | 1.30e-10 | 1.33e-08 | 90 |
GO:004586133 | Oral cavity | NEOLP | negative regulation of proteolysis | 76/2005 | 351/18723 | 1.40e-09 | 9.80e-08 | 76 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411510 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
hsa0411515 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
hsa0411524 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
hsa0411534 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
hsa041159 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
hsa0411514 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
hsa0411523 | Oral cavity | LP | p53 signaling pathway | 38/2418 | 74/8465 | 2.82e-05 | 1.92e-04 | 1.24e-04 | 38 |
hsa0411533 | Oral cavity | LP | p53 signaling pathway | 38/2418 | 74/8465 | 2.82e-05 | 1.92e-04 | 1.24e-04 | 38 |
hsa041158 | Prostate | BPH | p53 signaling pathway | 30/1718 | 74/8465 | 5.15e-05 | 3.40e-04 | 2.10e-04 | 30 |
hsa0411513 | Prostate | BPH | p53 signaling pathway | 30/1718 | 74/8465 | 5.15e-05 | 3.40e-04 | 2.10e-04 | 30 |
hsa0411522 | Prostate | Tumor | p53 signaling pathway | 29/1791 | 74/8465 | 2.99e-04 | 1.65e-03 | 1.02e-03 | 29 |
hsa0411532 | Prostate | Tumor | p53 signaling pathway | 29/1791 | 74/8465 | 2.99e-04 | 1.65e-03 | 1.02e-03 | 29 |
hsa04115 | Stomach | GC | p53 signaling pathway | 13/708 | 74/8465 | 7.76e-03 | 4.10e-02 | 2.88e-02 | 13 |
hsa041151 | Stomach | GC | p53 signaling pathway | 13/708 | 74/8465 | 7.76e-03 | 4.10e-02 | 2.88e-02 | 13 |
hsa041152 | Stomach | CAG with IM | p53 signaling pathway | 12/640 | 74/8465 | 9.02e-03 | 4.86e-02 | 3.41e-02 | 12 |
hsa041153 | Stomach | CAG with IM | p53 signaling pathway | 12/640 | 74/8465 | 9.02e-03 | 4.86e-02 | 3.41e-02 | 12 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SERPINB5 | SNV | Missense_Mutation | c.781N>G | p.Pro261Ala | p.P261A | P36952 | protein_coding | deleterious(0.03) | possibly_damaging(0.899) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
SERPINB5 | SNV | Missense_Mutation | novel | c.580N>G | p.Pro194Ala | p.P194A | P36952 | protein_coding | deleterious(0.05) | benign(0.011) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
SERPINB5 | SNV | Missense_Mutation | novel | c.519N>T | p.Lys173Asn | p.K173N | P36952 | protein_coding | tolerated(0.09) | probably_damaging(0.983) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
SERPINB5 | insertion | In_Frame_Ins | novel | c.942_943insATGGTG | p.Ala314_Leu315insMetVal | p.A314_L315insMV | P36952 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SERPINB5 | deletion | Frame_Shift_Del | c.665delN | p.Asn223IlefsTer59 | p.N223Ifs*59 | P36952 | protein_coding | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
SERPINB5 | SNV | Missense_Mutation | novel | c.193G>T | p.Asp65Tyr | p.D65Y | P36952 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERPINB5 | SNV | Missense_Mutation | novel | c.892A>C | p.Ser298Arg | p.S298R | P36952 | protein_coding | deleterious(0) | benign(0.051) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERPINB5 | SNV | Missense_Mutation | c.329N>T | p.Arg110Ile | p.R110I | P36952 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
SERPINB5 | SNV | Missense_Mutation | novel | c.702N>T | p.Lys234Asn | p.K234N | P36952 | protein_coding | tolerated(0.22) | possibly_damaging(0.822) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SERPINB5 | SNV | Missense_Mutation | c.1015G>A | p.Ala339Thr | p.A339T | P36952 | protein_coding | tolerated(0.35) | benign(0.011) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |